CTL 119

Drug Profile

CTL 119

Alternative Names: Humanised anti-CD19 CAR T cells

Latest Information Update: 03 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Pennsylvania
  • Developer Novartis; University of Pennsylvania
  • Class CAR-T cell therapies
  • Mechanism of Action CD19 antigen modulators; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I B cell prolymphocytic leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Clinical Phase Unknown Chronic lymphocytic leukaemia

Most Recent Events

  • 09 Dec 2017 Phase-I clinical trials in Acute lymphoblastic leukaemia (In adolescents, In children, In adults, Second-line therapy or greater) in USA prior to December 2017 (IV)
  • 09 Dec 2017 Phase-I clinical trials in B-cell prolymphocytic leukaemia (In adolescents, In children, Second-line therapy or greater, In adults) in USA prior to December 2017 (IV)
  • 09 Dec 2017 Safety and efficacy data from a phase I trial in B-cell prolymphocytic leukaemia and Acute lymphoblastic leukaemia presented at the 59th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top